Clinical Trial of TQB3002 in Patients With Advanced Cancers

Inclusion Criteria: * Subjects voluntarily joined this study, signed the informed consent form, and had good compliance； * Age: ≥ 18 years old; Eastern Cooperative Oncology Group (ECOG) score: 0-1 ; Expected survival of more than 3 months； * Histologically or cytologically diagnosed with advanced cancers * Subjects with advanced malignancies who have failed standard therapy or lack effective treatment * Major organs are functioning well； * Female and male subjects of childbearing potential should agree to practice contraception for the duration of the study and for 6 months after the end of the study. Exclusion Criteria: * Current concomitant presence of other malignancies within 5 years prior to the first dose； * Unresolved toxicity above CTCAE Grade 1 due to any prior anti-tumor therapy * Significant surgical treatment, biopsy, or significant traumatic injury within 4 weeks prior to the first dose * Long-term unhealed wounds or fractures * Cerebrovascular accident (including transient ischemic attack, intracerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism within 6 months prior to the first dose * Swallowing dysfunction, active gastrointestinal diseases or other diseases that significantly affect the absorption, distribution, metabolism and excretion of the study drug, or previous subtotal gastrectomy * A history of psychotropic drug abuse and cannot be abstained from or have a mental disorder * Subjects with any severe and/or uncontrolled disease